ArticleGels (Basel, Switzerland)2022
Tacrolimus-Loaded Solid Lipid Nanoparticle Gel: Formulation Development and In Vitro Assessment for Topical Applications.
Article in Gels (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Hyaluronic Acid-functionalized Hesperidin-loaded Solid Lipid Nanoparticles for Mitigating Oxidative Stress: A Potential Strategy for Radiation-induced Skin Injury.Applied biochemistry and biotechnology · 2026Article
- Nanotechnology based topical drug delivery systems for psoriasis addressing current strategies clinical progress and manufacturing challenges.Discover nano · 2026Review
- Nanotechnology in Dermatology: A Comprehensive Narrative Review of Performance, Safety, and Clinical Translation.Health science reports · 2026Article
- Innovative HPMC/PVP K90 Dissolving Microneedles Incorporating Tacrolimus-Loaded Cubosomes: A Novel Strategy for Managing Allergic Conjunctivitis.Pharmaceutics · 2026Article
- Curcumin-piperine liposomal hydrogel formulation for topical management of atopic dermatitis and associated skin inflammation: optimization, in vitro and in vivo studies.Inflammopharmacology · 2026Article
- Phosphodiesterase 4 (PDE4) Inhibitor in Atopic Dermatitis: Impact of Nanocrisaborole on Biopharmaceutical Performance and Treatment Outcomes.Mini reviews in medicinal chemistry · 2026Review
- Emerging Trends in Transdermal Drug Delivery: Nanoparticle Formulations and Technologies for Enhanced Skin Penetration and Drug Efficiency.Pharmaceutical nanotechnology · 2026Review
- Progress in the clinical use of bone marrow aspirate concentrate for knee osteoarthritis: an expert opinion.Journal of orthopaedic surgery and research · 2025Review
- Transdermal Drug Delivery Systems in Atopic Dermatitis: A Review of Vehicle Innovation and Skin Barrier Challenges.Cureus · 2025Review
- Novel drug delivery systems in topical treatment of atopic dermatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Development of a Novel Drug Delivery System "Nanoemulfoam" for Topical Delivery of Terbinafine Hydrochloride as a Repurposed Therapy in Skin Cancer: Formulation, Optimization, In Vitro Characterization, Ex Vivo Transdermal Permeability, Cytotoxicity Studies, and In Silico Assessment.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Gels as Promising Delivery Systems: Physicochemical Property Characterization and Recent Applications.Pharmaceutics · 2025Review
- Deep-insights: Nanoengineered gel-based localized drug delivery for arthritis management.Asian journal of pharmaceutical sciences · 2025Review
- Tacrolimus: Physicochemical stability challenges, analytical methods, and new formulations.International journal of pharmaceutics: X · 2024Review
- New Insight for Enhanced Topical Targeting of Caffeine for Effective Cellulite Treatment: In Vitro Characterization, Permeation Studies, and Histological Evaluation in Rats.AAPS PharmSciTech · 2024Article
- Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review).International journal of molecular medicine · 2024Review
- Recent Advances in Phytochemical-Based Topical Applications for the Management of Eczema: A Review.International journal of molecular sciences · 2024Review
- Formulation and characterization of cholesterol-based nanoparticles of gabapentin protecting from retinal injury.Frontiers in chemistry · 2024Article
- 5-Fluorouracil-Loaded Hyaluronic Acid-Coated Niosomal Vesicles: Fabrication and Ex Vivo Evaluation for Skin Drug Delivery.ACS omega · 2023Article
- Preparation and In Vitro Evaluation of Levofloxacin-Loaded Floating Tables Using Various Rate-Controlling Agents.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The currently available topical formulations of tacrolimus have minimal and variable absorption, elevated mean disposition half-life, and skin irritation effects resulting in patient noncompliance. In our study, we fabricated tacrolimus-loaded solid lipid nanoparticles (SLNs) that were converted into a gel for improved topical applications. The SLNs were prepared using a solvent evaporation method and characterized for their physicochemical properties. The particle size of the SLNs was in the range of 439 nm to 669 nm with a PDI of ≤0.4, indicating a monodispersed system. The Zeta potential of uncoated SLNs (F1-F5) ranged from -25.80 to -15.40 mV. Those values reverted to positive values for chitosan-decorated formulation (F6). The drug content and entrapment efficiency ranged between 0.86 ± 0.03 and 0.91 ± 0.03 mg/mL and 68.95 ± 0.03 and 83.68 ± 0.04%, respectively. The pH values of 5.45 to 5.53 depict their compatibility for skin application. The surface tension of the SLNs decreased with increasing surfactant concentration that could increase the adherence of the SLNs to the skin. The release of drug from gel formulations was significantly retarded in comparison to their corresponding SLN counterparts (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.